2seventy bio sold full rights to a hemophilia A program and in vivo gene editing technology to partner Novo Nordisk.

HemoCue AB has unveiled a new cloud-based solution aimed at dramatically reducing the widespread prevalence of anemia in developing countries. The multinational plans to roll out the system first in India where the blood deficiency is a major health concern.

At $1.8 billion, Q2 device financing nearly doubled the Q1 total, mainly from an increase in IPOs and early VC rounds, and acquisitions were slightly higher at $4.7 billion. Diagnostics funding also increased to $784 million from Q1's $597 million, and Danaher's monster $13.8 billion buy of life sciences company Pall headlined the second quarter's $15.6 billion total in diagnostics M&A activity.

Device and diagnostics companies both suffered declines in fundraising compared with previous quarters. The biggest medtech acquisition was Stryker’s $1.4 billion buyout of MAKO, while in diagnostics BioMeriux’s $450 million purchase of BioFire topped the list.